Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

51 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-24

Study Completion Date

2020-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is associated with hyperactivation of the endocannabinoid system, and its inhibition by the administration of CB1 receptor (CB1R) antagonists, leads to a decrease in food intake, weight loss and an improvement in metabolic parameters. Even though the reduction in food intake following central CB1R inactivation seems to be the principal cause of weight loss and the improvement in metabolic parameters, several studies in animals and humans have indicated that peripheral CB1R could also be implicated in the regulation of glucolipid metabolism. As a result, it has been suggested that the long-term beneficial effects of inactivation of the endocannabinoid system are due to both central effects on food intake and peripheral effects involving adipose tissue, the liver, skeletal muscle and the pancreas. It appears essential to determine the role of CB1R located in peripheral tissues and in particular in adipose tissue, which plays an active role in maintaining glucolipid homeostasis. The experiments conducted in this project consist in studying in biopsies of abdominal subcutaneous fat whether activation of adipocyte CB1R modifies adipocyte metabolism by determining the mechanisms. The investigators hypothesize that activation of CB1R in adipose tissue will lead to the stimulation of lipolysis dependent on the alteration of the insulin signal, and therefore that inactivation of the endocannabinoid system by blocking peripheral CB1R could constitute a therapeutic approach to improve obesity-related insulin resistance and dyslipidaemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cryoablation for Obesity Management

NCT03092778

Obesity

COMPLETED NA

Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women

NCT02672826

Obesity

COMPLETED NA

MOTIVATE Weight Loss Study

NCT01679158

Obesity

COMPLETED NA

Endoscopic Sleeve Gastroplasty for Treatment of Obesity

NCT02231970

Obesity

UNKNOWN NA

Safety and Efficacy of Laparoscopic Truncal Vagotomy for the Treatment of Obesity

NCT00285220

Morbid Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hernia Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Samples of adipose tissue

Intervention Type PROCEDURE

Samples of visceral and subcutaneous adipose tissue collected during hernia surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Samples of adipose tissue

Samples of visceral and subcutaneous adipose tissue collected during hernia surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men aged 18 to 70 years
* persons who have provided oral consent
* persons undergoing surgery for hernia

* men aged 18 to 70 years
* BMI \> 30
* persons who have provided oral consent
* persons undergoing surgery for hernia

* men aged 18 to 70 years
* type 2 diabetic not treated with Insulin or GLP-1 agonist
* BMI \> 30
* persons who have provided oral consent
* persons undergoing surgery for hernia

Exclusion Criteria

* persons without health insurance cover
* BMI \> 30
* diabetes
* associated diseases: cancer, chronic inflammatory diseases
* adults under guardianship

obese subjects

* persons without health insurance cover
* diabetes
* associated diseases: cancer, chronic inflammatory diseases
* adults under guardianship

diabetic obese subjects

* persons without health insurance cover
* associated diseases: cancer, chronic inflammatory diseases
* adults under guardianship

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No